Journal of Cardiothoracic and Vascular Anesthesia
Volume 22, Issue 6 , Pages 806-810, December 2008

Drug-Eluting Stents: Patient Understanding of the Risks of Premature Cessation of Antiplatelet Drugs

  • Terrence L. Trentman, MD

      Affiliations

    • Department of Anesthesiology, Mayo Clinic, Scottsdale, AZ
    • Corresponding Author InformationAddress reprint requests to Terrence L. Trentman, MD, Department of Anesthesiology, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ 85054
  • ,
  • David M. Rosenfeld, MD

      Affiliations

    • Department of Anesthesiology, Mayo Clinic, Scottsdale, AZ
  • ,
  • David R. Danielson, MD

      Affiliations

    • Department of Anesthesiology, Mayo Clinic, Rochester, MN
  • ,
  • Susan G. Hagstrom, MD

      Affiliations

    • Department of Anesthesiology, Mayo Clinic, Scottsdale, AZ

published online 24 June 2008.

Objective

Drug-eluting coronary stent use is common. Antiplatelet drug use after stent placement is necessary to prevent stent thrombosis. It has been recommended that at the time of stent placement, patients be given instructions regarding stopping antiplatelet drugs before elective surgery. Unfortunately, patients may be given inappropriate preoperative instructions by health care providers or may stop the drugs on their own. This can lead to perioperative myocardial infarctions and death.

Design

Survey.

Setting

Preoperative evaluation clinic of 2 teaching hospitals.

Participants

One hundred sixteen patients with coronary stents completed a 13-question survey. The questionnaire assessed patient understanding of stent type and the risks of stopping antiplatelet drugs, in addition to communication among the patient, their surgeon, and their treating cardiologist before elective surgery.

Intervention

None.

Measurements and Main Results

The majority of patients stated either they had received no instructions from their implanting cardiologist regarding future surgery and antiplatelet drugs or they were unsure if any instructions had been given. Most patients (57%) received antiplatelet instructions regarding their planned surgery from their surgeon, whereas only 14% received instructions with (known) cardiology input. The majority of patients were unaware or unsure of any risk in prematurely stopping their antiplatelet drugs.

Conclusion

Many patients are unaware of their stent type and the risks of inappropriately stopping antiplatelet drugs. Furthermore, they may have received either inappropriate preoperative instructions or no instructions at all. The opportunity exists to improve preoperative communication with patients in order to minimize perioperative thrombotic risks of coronary stents.

Key Words: drug-eluting stent, bare-metal stent, stent thrombosis, antiplatelet drug, perioperative myocardial infarction

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1053-0770(08)00112-2

doi:10.1053/j.jvca.2008.04.021

Journal of Cardiothoracic and Vascular Anesthesia
Volume 22, Issue 6 , Pages 806-810, December 2008